Navigation Links
CV Therapeutics' Anti-Ischemic Therapy Ranexa(R) Significantly Reduces Cardiac Chest Pain Symptoms and Recurrent Ischemia in MERLIN-TIMI 36 Patients With Angina
Date:4/1/2008

n this population of patients with coronary artery disease, which included nearly 1,100 patients with prior heart failure. Ranolazine had no effect on the risk of CV death or MI in the study.

About Angina

Chronic angina is a serious and debilitating heart condition, usually associated with coronary artery disease and marked by repeated and sometimes unpredictable attacks of chest pain. Approximately 8.9 million people in the United States have chronic angina, and 400,000 new cases are diagnosed annually, according to the American Heart Association. Ranexa has anti- ischemic effects which do not depend on changes in heart rate or blood pressure.

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company primarily focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.

CV Therapeutics' approved product, Ranexa(R) (ranolazine extended-release tablets), is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates.

CV Therapeutics' clinical and preclinical drug development candidates and programs include regadenoson, which is being developed for potential use as a pharmacologic stress agent in myocardial perfusion imaging studies. Regadenoson has not been determined by any regulatory authorities to be safe or effective in humans for any use.

Except for the historical information contained herein, the matters set forth in this press release, including statements as to research and development and commercialization of products, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject t
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Michael J. Fox Foundation Commits up to $10 Million for Pre-Clinical Drug Development Under Therapeutics Development Initiative
2. Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions
3. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
4. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
5. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
6. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
7. Ception Therapeutics Initiates Phase II/III Clinical Trial for Its Lead Product Reslizumab in Eosinophilic Esophagitis (EE) in Children
8. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
9. InteKrin Therapeutics Announces Initiation of Phase 2b Study in Type 2 Diabetes with INT131
10. Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics
11. TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014 Yesterday, former Congressman ... medical device manufacturing facility. Rep. Kennedy and ... monitors facilitate cutting-edge research in neurological disease and ... mental health advocate, Garen Staglin , created ... fostering fundamental changes that will radically accelerate the ...
(Date:7/10/2014)... , July 10, 2014  Valeant Pharmaceuticals International, Inc. ... announced it has completed the sale to Galderma of ... owned or held by Valeant for $1.4 billion in ... S.A, which recently completed its acquisition of Galderma. ... of our products to a company that is firmly ...
(Date:7/10/2014)... , July 10, 2014  Decision Resources ... surveyed infectious disease (ID) specialists are willing to ... Orbactiv (oritavancin) for use as OPAT, approximately two-thirds ... these agents to their hospital inpatients. However, our ... OPAT patients are initiated on OPAT following hospital ...
Breaking Medicine Technology:Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3
... NORRITON, Pa., Aug. 15, 2011 Tengion, Inc. (Nasdaq: ... Jorkasky, M.D., who recently joined Endo Pharmaceuticals (Nasdaq: ... Medical Officer, to its Board of Directors. ... at Quaker BioVentures, is stepping down from the Tengion Board ...
... Adeona Pharmaceuticals, Inc. (AMEX: AEN ), a developer ... its second quarter 2011 financial results for the period ended June ... second quarter. Updates since the beginning of the ... Multiple Sclerosis (MS) As ...
Cached Medicine Technology:Tengion Appoints Diane Jorkasky, M.D., to its Board of Directors 2Adeona Reports Second Quarter 2011 Financial Results 2Adeona Reports Second Quarter 2011 Financial Results 3Adeona Reports Second Quarter 2011 Financial Results 4Adeona Reports Second Quarter 2011 Financial Results 5Adeona Reports Second Quarter 2011 Financial Results 6Adeona Reports Second Quarter 2011 Financial Results 7Adeona Reports Second Quarter 2011 Financial Results 8Adeona Reports Second Quarter 2011 Financial Results 9
(Date:7/13/2014)... Seattle, WA (PRWEB) July 13, 2014 According ... Vkool.com, this is a step by step guide on what ... impairment easily and quickly. Vkool writes in its review ... what foods to eat to revitalize their kidney health. Vkool ... book can help people reverse their damaged kidney functions naturally. ...
(Date:7/13/2014)... 13, 2014 Celebrity fitness trainer and ... a promotional partnership with Aqua Health Labs for their ... EPA supplement . The collaboration was recently announced live ... fitness trainer , actor, model, and a two time ... A-List celebrities, he has prepared stars including Demi Moore, ...
(Date:7/13/2014)... If Dr. Lawrence Power has his way, the ... http://www.HealthYourself101.com will expand people’s understanding of the causes, ... set out to provide a health education platform on this ... we say it? – entertaining to dig into and learn ... the remote learner – the solitary individual signing on from ...
(Date:7/13/2014)... July 13, 2014 Recently, iFitDress.com, one ... women’s special occasion outfits, has added a new selection ... Furthermore, the company has launched a promotion for these ... , iFitDress.com is now providing thousands of graceful ... sell well in Britain, America, France, Italy and many ...
(Date:7/12/2014)... July 13, 2014 Recently, iFitDress.com, one of ... selection of red evening gowns . What’s more, all ... 56% off. , The company’s senior spokesman states, “We are ... on our website is an enjoyable shopping experience. In addition ... our online store, low prices do not always mean bad ...
Breaking Medicine News(10 mins):Health News:Kidney Disease Solution Book Review Exposes Duncan Capicchiano's Newly Updated Kidney Disease Treatment Plan – Vkool.com 2Health News:Kidney Disease Solution Book Review Exposes Duncan Capicchiano's Newly Updated Kidney Disease Treatment Plan – Vkool.com 3Health News:Celebrity Fitness Expert Supports Revolutionary New Health Supplement 2Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 2Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 3Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 4Health News:New and Beautiful Evening Dresses Unveiled by iFitDress.com 2Health News:Discounted Red Evening Gown Announced by iFitDress.com 2
... and France signed a landmark cooperative treaty here Thursday ... expected by practitioners to help in the fight against ... cooperate in academic and clinical TCM research, setting new ... practice and developing new TCM products, said the document ...
... city's eastern fringe towards the airport, a signboard on the ... by Maneka Gandhi's People for Animals (PFA). ... day comes true. This sprawling pound aims to restore the ... focuses on anti-rabies vaccination for the canines. ,"We ...
... can prevent [chronic diseases], more people can live longer.',Rapid advances ... are bringing// closer the time when many people can achieve ... Dr. Pascal Goldschmidt, dean of the University of Miami Miller ... we will see diagnostic tools and therapies that will change ...
... in Los Angeles, it was reported that AIDS cases have ... Jaffe, a professor of medicine at Oxford University in England, ... ,He also called for a new approach to ... emphasized on the scientific approach rather than moral and religious ...
... women have been asked to keep a strict watch on ... , The appeal has come from UK’s government watchdog group ... , According to them, one in every seven women ... pregnancy. This refers also to the ‘baby blues’ that quite ...
... it is possible to use a resin filter to ... infected animal, //a finding that has major implications for ... associated with variant Creutzfeldt-Jakob disease, mad cow disease, scrapie ... transfusions. ,Dr. Ruben Carbonell, Frank Hawkins Kenan ...
Cached Medicine News:Health News:An Anti-rabies Campaign With Bite 2Health News:An Anti-rabies Campaign With Bite 3Health News:Genetics Might Engineer Path to Successful Aging 2Health News:'Baby Blues’-no Tiny Proble 2Health News:Researchers Develop Resin Beads That Capture Mad Cow Disease Agent From Blood 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: